07:00 , Jul 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Monoamine oxidase A (MAO-A) Mouse and human sample studies suggest inhibiting MAO-A could help prevent prostate cancer growth and metastasis. In mouse xenograft...
08:00 , Jan 27, 2014 |  BioCentury  |  Emerging Company Profile

Salarius: Kicking LSD

Salarius Pharmaceuticals LLC is using a fragment-based discovery approach to develop safer inhibitors of lysine-specific histone demethylase, an epigenetic target that is up-regulated in hormone-dependent cancers and essential in specific forms of acute myelogenous leukemia...
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Psychosis; emotional lability NMDA receptor NR2A subtype (GRIN2A; NR2A); GRIN2B (NR2B) Mouse studies suggest NR2A and NR2B antagonists could help treat aggressive behavior. Humans and...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

TriRima: Phase II started

CeNeRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 125 mg TriRima twice daily in 360 patients. CeNeRx has rights to TriRima from Krenitsky under a 2005 deal. CeNeRx BioPharma Inc. , Cary,...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

Indantadol: Development discontinued

Vernalis discontinued its V3381 development program after interim data from a pilot trial in patients with chronic cough showed that the compound displayed only marginal efficacy and exhibited issues relating to tolerability. Further details were...
08:00 , Nov 22, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Amgen Inc. (NASDAQ:AMGN) gained $0.53 to $55 last week after FDA approved an sBLA for Xgeva denosumab to prevent skeletal-related events in patients with bone metastases from solid tumors (see " Full Speed...
02:00 , Nov 19, 2010 |  BC Extra  |  Clinical News

Vernalis discontinues V3381 program

Vernalis plc (LSE:VER) discontinued its V3381 development program after interim data from a pilot trial in patients with chronic cough showed that the compound displayed only marginal efficacy and exhibited issues related to tolerability. Further...
23:10 , Aug 13, 2010 |  BC Extra  |  Financial News

CeNeRx raises $13 million

CeNeRx BioPharma Inc. (Cary, N.C.) raised $13 million in a series C round from existing investors Perseus Soros Biopharmaceutical Fund; L Capital Partners; and Pappas Ventures. CeNeRx plans to start a Phase II trial for...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Indantadol: Preliminary Phase IIb data

Top-line data from the international Phase IIb IN-STEP trial in 162 patients with neuropathic pain due to diabetes showed that twice-daily V3381 missed the primary endpoint of significantly reducing mean pain scores from baseline vs....
00:47 , Mar 25, 2010 |  BC Extra  |  Clinical News

Vernalis falls on V3381 data

Vernalis plc (LSE:VER) fell 14p (19%) to 60p on Wednesday after V3381 missed the primary endpoint of significantly reducing mean pain scores from baseline vs. placebo in the Phase IIb IN-STEP trial to treat neuropathic...